
    
      This is a study involving a 12 week treatment phase. During the treatment phase subjects
      receive FLUTIFORM® or Sertetide®. Efficacy will be assessed by lung function tests and asthma
      symptoms, sleep disturbance. Safety will be assessed by adverse events, vital signs, lab
      tests and ECGs.
    
  